AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

PRESS RELEASE: AltaRex announces cancer collaboration with Epigen.

Chemical Business Newsbase

| June 12, 2001 | COPYRIGHT 2000 Elsevier Engineering Information, Inc. (Hide copyright information)Copyright

AltaRex Corp has signed a Memorandum of Understanding establishing a joint collaboration with Epigen Inc for the purposes of the research and development of antibody based treatments for a potential twelve cancers associated with the human carcinoma antigen (HCA).

HCA is Epigen's proprietary cancer specific antigen that appears in circulation in early stage disease and is associated with the vast majority of epithelial cancers including prostate, ovarian, breast and non-small cell lung cancers.

The companies expect to enter into a definitive agreement within 60 days.

Epigen brings to the collaboration the antigen HCA and a series of foreign …

Related articles from newspapers, magazines, journals, and more
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily